ABSTRACT-We examined the effects of KW-3635, a thromboxane (TX) A2-receptor antagonist, and OKY-046, a TX synthetase inhibitor, on the prostaglandin (PG) 12 production in endothelium-intact and -in jured guinea pig aorta and compared them with those of aspirin. In the endothelium-intact aorta, both the low (3 mg/kg) and the high (100 mg/kg) dose of aspirin similarly reduced the PGI2 production, as measured ex vivo 1 hr after the injury. In contrast, neither KW-3635 (10 mg/kg) nor OKY-046 (30 mg/kg) inhibited the PGI2 production. The endothelial injury, induced by balloon catheterization, caused a reduction of PGI2 production in the aorta and decline of plasma PGI2/TXA2 ratio. In the endothelium-injured animals, the high dose of aspirin further reduced the PGI2 production in the aorta, whereas KW-3635 and OKY-046 did not affect it. KW-3635 and OKY-046 also ameliorated the reduced ratio of PGI2/TXA2 in the plasma. The present results demonstrate that aspirin, but not KW-3635 or OKY-046, reduces the PGI2 production in the aorta either in the endothelium-intact or -injured state. It is thus suggested that the TXA2-receptor an tagonist and the TX synthetase inhibitor have some advantages over aspirin when used for the prevention of acute thrombosis after percutaneous transluminal angioplasty.
Percutaneous transluminal angioplasty (PTA) has re cently been the prevailing treatment for occlusive athero sclerotic disease in humans. Although the primary success rate for PTA reaches 90076, there is a considerable rate of restenosis, up to approx. 30076 (1) (2) (3) (4) . The platelet adhe sion early after angioplasty and intimal hyperplasia are supposed to be responsible for abrupt reocclusion and restenosis, respectively. After angioplasty, platelets ad here to the exposed subendothelial connective tissues or media in only a few minutes (5, 6) . Adherent platelets then discharge not only various granular components to enhance the aggregatory response but also a variety of platelet-derived growth factors, which increase the migra tory or the mitogenic activity of smooth muscle cells (7, 8) . Therefore, early platelet aggregation appears to play a pivotal role in the occurrence of postangioplasty throm botic occlusion and restenosis (9) . One of the important factors involved in the process may be the locally reduced production of prostaglandin (PG) 12, which is a potent inhibitor of platelet aggregation (10) . In fact, destruction or injury of the endothelium by balloon angioplasty is known to cause the reduction of PGI2 synthesis in the ves sel (11, 12) .
To prevent thrombosis after PTA, medication with vari ous drugs including antiplatelet agents has been advocat ed (13) . Aspirin, a cyclooxygenase inhibitor, is a potent inhibitor of platelet aggregation and is frequently prescribed for patients who underwent PTA so as to pre vent abrupt reocclusion. The activity of aspirin is mainly based on its irreversible inhibition of platelet cyclooxy genase, resulting in the prevention of synthesis of the proaggregating thromboxane (TX) A2. However, the an tiaggregatory effect of aspirin may be offset by the con current inhibition of vascular cyclooxygenase, leading to the decrease in the PGI2 producing ability. As the platelets from guinea pigs are quite similar to those from humans with regard to the response to agonists and antagonists of the eicosanoids (14) , it would be preferable to use guinea pigs to study a response that is dependent on platelets. However, so far, guinea pigs have rarely been used as an experimental PTA model (15) . The purposes of the present study using guinea pigs were: 1) to determine whether PGI2 production after experimental balloon angioplasty is lowered or not and 2) to delineate the effects of aspirin, KW-3635, a TXA2-receptor an tagonist (16) and OKY-046, a TX synthetase inhibitor (17) , on the aortic PGI2 production in either the normal stare or in the injury state. 
MATERIALS AND METHODS
Male Hartley guinea pigs weighing 400-550 g (Japan Shizuoka Laboratory Animal Center, Inc., Hamamatsu) were used. Animals were randomly assigned to 2 groups, the endothelium intact group and the endothelium in jured one. Each group consisted of the following 5 sub groups, each including 6 animals: 1: vehicle-treated, 2: aspirin (3 mg/kg)-treated, 3: aspirin (100 mg/kg)-treated, 4: KW-3635 (10 mg/kg)-treated, and 5: OKY-046 (30 mg/kg)-treated. In addition to the above groups, a sham operated group was set up. The doses of aspirin were determined according to the previous report (18): we used a low dose, 3 mg/kg, that did not inhibit sodium arachidonate (100 tM)-induced ex vivo platelet aggrega tion in guinea pigs 2 hr after administration and a high dose, 100 mg/kg, that completely inhibits the aggrega tion. The dose of KW-3635 examined, 10 mg/kg, was the minimum effective dose to inhibit the aggregation (18) . The dose of OKY-046 was determined by a preliminary study examining the TXB2 concentration in the serum. At the dose of 30 mg/kg, it almost completely prevented the elevation of TXB2, which was elicited by intravenous in jection of sodium arachidonate 2 hr after the drug treat ment. The drug or the vehicle was administered 1 hr be fore the aortic endothelial injury, as described below; i.e., 2 hr before the withdrawal of blood and sacrifice of the animal. Several guinea pigs, with endothelium intact or in jured aorta, were used for histological studies. 
Endothelial injury
Endothelial injury was produced with a slight modifica tion of the method described by McCaffrey et al. (19) . In brief, 1 hr after the drug administration, the guinea pig was anesthetized with pentobarbital sodium (35 mg/kg, i.p.). The left carotid artery was exposed and a 2F Fog arty balloon catheter (Baxter Healthcare Corporation, Irvine, CA, USA) was inserted 10 cm to the level of just proximal to the abdominal bifurcation. The balloon was then inflated with an inflator (Boston Scientific Corpora tion, Watertown, MA, USA) at 1.5 atm. The balloon was gently withdrawn to the level of the aortic arch and then deflated. This procedure was repeated 4 times. Sham-oper ated animals were subjected to the same procedure except the balloon was not inflated.
Collecting blood samples
In the endothelium-injured animal (under anesthesia), the blood was collected from the abdominal aorta 1 hr after the balloon catheterization (i.e., 2 hr after the drug administration). The endothelium-intact animal was anes thetized with sodium pentobarbital (35 mg/kg, i.p.) 2 hr after the drug administration, and then the blood was collected from the abdominal aorta. The animals were sacrificed by the massive blood withdrawal. The collected blood was mixed with 1 / 10 volume of 77 mM EDTA • 2Na containing 10-4 M indomethacin and thereafter centri fuged at 3000 rpm for 10 min. The obtained plasma was stored at -35V until analyzed.
Histological examination
One hour after the balloon catheterization, the thoracic aorta was removed, washed thoroughly with saline and fixed in 10% neutral buffered formaldehyde. The aorta was dissected longitudinally and embedded in paraffin in a conventional manner. Each section was stained with hematoxylin and eosin, and it was examined histological ly by light microscopy. The presence or absence of endo thelial cells and mural thrombus and the extent of inti mal thickening were examined in a "blind" manner.
PGI2 production in aorta
After collecting the blood sample, the thoracic aorta from aortic arch to diaphragm was carefully removed and the surrounding connective tissues were freed and discard ed. The aorta was cut into 15-mm ring segments and pre incubated for 15 min in 3 ml of physiologically balanced salt solution of the following composition (20) : 124 mM NaCl, 5 mM KH2PO4i 1.25 mM MgSO4, 1.45 mM CaC12, 1.25 mM KH2PO4, 25 mM Hepes and 8 mM glucose. The solution was maintained at 37C and was oxygenated with a gas mixture of 95010-02 and 5%-CO2. After a 15-min in cubation, the incubation medium was exchanged, and the pre-incubation was continued for another 1 hr, during which time the production of PGI2 reached a steady-state. Thereafter, the medium was exchanged and incubation was continued for another 30 min. This medium was stored at -35 *C until measured. A 100-tcl aliquot of the incubation medium was used for radioimmunoassay (RIA).
RIA analysis PGI2 and TXA2 were measured as 6-keto-PGFIa and TXB2, the stable hydrolyzed products of PGI2 and TXA2, respectively, as described by Maclouf (21) and Fitzpatrick (22) . The concentration of 6-keto-PGFIa in the incuba tion medium and the concentrations of 6-keto-PGFIa and TXB2 in the plasma were determined by RIA. The work ing buffer used was 0.1 M potassium phosphate buffer, pH 7.4, containing 0.9% (w/v) NaCl, 0.01010 (w/v) NaN3 and 0.1010 (w/v) gelatin. Antiserum for 6-keto-PGFIa or TXB2 was diluted 10,000 or 30,000 times, respectively, with the working buffer.
[3H]6-Keto-PGFIa or [3H]TXB2 (New England Nuclear, Boston, MA, USA) (0.1 ml), 0.1 ml of anti-6-keto-PGFIa antiserum or anti-TXB2 antise rum, respectively, 0.2 ml of the working buffer and 0.1 ml of the sample were mixed. After incubation for 16 hr at 41C, 1 ml of 0.5% charcoal/0.05% dextran T70 suspen sion in the working buffer was added to the assay mixture. The mixture was allowed to stand for 15 min and then cen trifuged at 1,000 x g for 10 min at 41C. The radioactivity in the supernatant was counted with a liquid scintillation counter (Model 14530; Packard, Meriden, CT, USA). The cross-reactivity of anti-6-keto-PGFIa antiserum or anti-TXB2 antiserum with other prostaglandins was less than 2010 or 1%, respectively. Unlabeled 6-keto-PGFIa and TXB2 were purchased from Funakoshi Co., Ltd.
(Tokyo).
Drug treatment
Aspirin (Nacalai Tesque Inc., Kyoto), KW-3635 and OKY-046 were orally administered 2 hr before sacri fice. KW-3635 (sodium (E)-11-[2-(5,6-dimethyl-1-benz imidazolyl) ethylidene] -6,11-dihydrodibenz [b, e] oxepine 2-carboxylate monohydrate) and OKY-046 were synthe sized in our laboratories. All the drugs were suspended in 0.3% sodium carboxymethylcellulose (CMC) at an appropriate concentration so as to make the adminis tration volume 5 ml suspension per kg body weight. Guinea pigs that were administered only 0.3% CMC served as the control.
Statistical analyses
Results are expressed as means ± standard errors of 6 ex periments. Differences between two groups were analyzed by Student's t-test or the Aspin-Welch test. P values less than 0.05 were considered to be statistically significant.
RESULTS
The balloon angioplasty caused significant endothelial damage in the aorta. Formation of fibrinous thrombi over abraded intimal areas, directly on the denuded lamina elastica interna, was observed in patches (Fig. IA) . In the thrombus, some neutrophils, in addition to platelets, were present (Fig. 1 B) . Intimal thickening was not evident 1 hr after the balloon catheterization.
PGI2 production, measured as 6-keto-PGF,a, in either the endothelium-intact or the endotheliuminjured aorta, is shown in Fig. 2 . The 6-keto-PGF,a release from the aortas of vehicle-treated endothelium-intact (vehicle-intact) animals was not different from that of sham-operated animals (26.2-+2.7 and 29.3 ± 3.8 ng/ 100 mg dry weight/30 min, respectively). Aspirin at doses of 3 and 100 mg/kg significantly reduced the 6-keto-PGF,a release from the aortas of endothelium-intact animals. Neither KW-3635 (10 mg/kg) nor OKY-046 (30 mg/kg) caused any effect on the 6-keto-PGF,a release in endothelium intact animals. After the endothelial injury by balloon catheterization, the 6-keto-PGF,a release from aortas was attenuated as compared with that in the vehicle-intact animals. Aspirin at a dose of 100 mg/kg significantly reduced the 6-keto-PGF,a release in endothelium-injured animals. KW-3635 (10 mg/kg) or OKY-046 (30 mg/kg) did not further reduce the 6-keto-PGF,a release, but rather tended to ameliorate the attenuation.
The effects on the plasma concentration of 6-keto PGF,,, are summarized in Fig. 3 . In endothelium-intact animals, the plasma concentration of 6-keto-PGF,a was significantly reduced by the treatment with aspirin (3 and 100 mg/kg). KW-3635 (10 mg/kg) did not affect the plas ma concentration of 6-keto-PGF,a. OKY-046 (30 mg/kg) significantly reduced it, although the reason for this is not clear. Following endothelial injury, the plasma concentra tion of 6-keto-PGF,a fell significantly as compared with that of the vehicle-intact animals. In the aspirin (3 and 100 mg/kg)-treated groups, the plasma concentration of 6-keto-PGF,a remained low, whereas in the KW-3635 (10 mg/kg) and OKY-046 (30 mg/kg)-treated groups, it recovered to almost the same level as that in the vehicle intact animals. The effects on the plasma concentration of TXB2 are summarized in Fig. 4 . In both endothelium-in tact and endothelium-injured animals, plasma TXB2 tend ed to be reduced by the treatment with aspirin (3, 100 mg/kg) and OKY-046 (30 mg/kg), presumably because of the inhibition of cyclooxygenase and TX synthetase, respectively. The effects on the ratio of 6-keto-PGF,a to TXB2 in the plasma are shown in Fig. 5 . There was no significant difference in the ratio between the sham-operated animals (1.74-L0.44) and the vehicle-intact animals (1.74± 0.19). In endothelium-intact animals, aspirin at doses of 3 and 100 mg/kg significantly reduced the ratio as compared with that of the vehicle-intact animals. Neither KW-3635 (10 mg/kg) nor OKY-046 (30 mg/kg) significantly affect ed the ratio. In the vehicle-treated endothelium-injured (vehicle-injured) animals, the ratio significantly declined, as compared with that of the corresponding endothelium intact animals, owing to the decrease in 6-keto-PGF,a and the increase in TXB2. In the endothelium-injured animals, the low dose (3 mg/kg) aspirin, KW-3635 (10 mg/kg) and OKY-046 (30 mg/kg) significantly increased the ratio as compared with that of the vehicle-injured animals. 
DISCUSSION
The present histological observation revealed the focal presence of platelet deposition and mural thrombus on the subendothelium of the endothelium-injured aorta.
This early platelet deposition and thrombus formation were also observed in the previous experimental studies (5, 7, 15) . As the vascular production of PGI2 is negative ly correlated with the platelet deposition (5, 15), the reduced production of PGI2 seems to, at least partly, be responsible for the platelet deposition on the subendo thelium of the injured aorta. In fact, the present results demonstrated that in guinea pigs, like in other species, vas cular production of PGI2 decreased following balloon catheterization. This observation is in accordance with the previous one by Tschopp and Baumgartner (15) who showed the same decline of PGI2 production in guinea pigs by using the bioassay system. It is thus reasonable to assume that the reduced production of PGI2 is involved in the platelet deposition and the formation of thrombus in the endothelium-injured aorta. In the endothelium-intact aorta, aspirin not only at 100 mg/kg, but even at 3 mg/kg reduced the production of PGI2. Aspirin at 3 mg/kg, does not inhibit the ex vivo platelet aggregation induced by either sodium arachidonate (100 pM) or collagen (3 pg/ml) (18) . Thus, the present result implies that aspirin even at the low dose, which does not affect platelet aggregation, could at tenuate the ability of the endothelium to produce PGI2. Indeed, the same phenomenon was also observed in nor mal volunteers and patients with atherosclerosis (23, 24) . Cumulative administration of a low dose (3 mg/kg) aspi rin significantly attenuated the production of PGI2 by the cephalic (23) and the saphenous vein (24) . In the present study, neither KW-3635 nor OKY-046, in contrast to aspirin, exerted any influence on the ability of aortas to produce PGI2 in endothelium-intact animals. The present observation suggest that even the single low dose of aspi rin might attenuate the ability of vessels to produce PGIZ.
In the endothelium-injured aorta, the high dose (100 mg/kg) of aspirin further reduced the PGI2 production, while the low dose (3 mg/kg) of this drug did not affect it. On the other hand, the aortic PGI2 production in KW 3635 (10 mg/kg) or OKY-046 (30 mg/kg)-treated animals was not reduced as compared with that of the vehicle injured animals. These results suggest that KW-3635 and OKY-046 may be more desirable drugs than the high dose aspirin since it reduced the production of PGI2 as well as TXA2. Furthermore, aspirin also has some drawbacks such as the well-known gastrointestinal adverse effect (25) and the sex difference in the response to the drug (26) . In addition, the PGI2 production by atheromatous vessels might be more easily inhibited by aspirin (27) . Consider ing these observations, the TXA2-receptor antagonist and the TX synthetase inhibitor may have some advantage over aspirin for the treatment of vascular thrombotic dis orders.
A significant portion of vascular PGI2 production originates from endothelial cells (12) . In the present study, indeed, when the endothelium was injured by balloon catheterization, the PGI2 production in the endothelium denuded aorta declined significantly, and platelet deposi tion and thrombus formation occurred simultaneously. Concomitantly with the reduced PGI2 production in the aorta, the plasma concentration of 6-keto-PGF1a was sig nificantly reduced while that of TXB2 tended to be in creased, resulting in a significant fall in the ratio of 6 keto-PGFIa/TXB2. The slight increase in plasma TXB2 is likely to be due to the platelet adhesion and activation on the injured subendothelium. Indeed, local platelet activa tion followed by excess release of TXA2 from the platelets can be a secondary cause of thrombus formation. KW 3635 significantly ameliorated the deteriorated ratio of plasma 6-keto-PGFIa/TXB2 following endothelial injury, probably due to the inhibition of the platelet aggregation at the site of endothelial injury. OKY-046 also significant ly recovered the ratio. Increased production of PGI2 from PGH2 by the inhibition of thromboxane synthetase (i.e., steal phenomenon) might have been highlighted when platelets were activated.
TXA2-receptor antagonists and TX synthetase inhibi tors have been shown to exert inhibitory effects on throm bus formation more potently than aspirin in several ex perimental models in animals (28 31) . Inhibitory effects of aspirin against thrombus formation vary according to the dose used (32, 33) . Generally speaking, the antithrom botic action of aspirin is observed in its lower doses. Thus, aspirin therapy requires careful deliberation. Fur ther studies are required to determine whether or not the TXA2-receptor antagonist or the TX synthetase inhibitor is more efficacious as an antithrombotic drug than aspi rin, especially in the clinical setting.
In the present study, a TXA2-receptor antagonist and a TX synthetase inhibitor produced similar effects on the aortic PGI2 production; however, these two types of anti platelet agents have different modes of action. The anti thrombotic effect of the TX synthetase inhibitor seems at least partly be mediated via the increased production of PGI2 (34) . On the other hand, the TXA2-receptor an tagonist, but not the TX synthetase inhibitor, antagonizes TXA2 and PGH2, both of which exhibit a potent proag gregatory action (35, 36) . Recently, the combined treat ment with a TXA2 receptor antagonist and a TX syn thetase inhibitor has been recommended (37, 38) . The combined treatment seems to be theoretically preferable, since it can lead to the inhibition of PGH2 as well as TXA2 and, moreover, to locally increased PGI2 at the site of thrombus.
In summary, we demonstrated the reduction of PGI2 production in the balloon catheterized aorta of the guinea pig. In the endothelium-intact aorta, both the low (3 mg/kg) and the high (100 mg/kg) doses of aspirin, but not KW-3635 or OKY-046, reduced the PGI2 production. In the endothelium-injured aorta, the high dose of aspirin further reduced the PGI2 production, whereas the low dose of aspirin, KW-3635 and OKY-046 did not further suppress the PGI2 production. These results suggest that the TXA2-receptor antagonist and the TX synthetase inhi bitor have some advantages over aspirin when used for the prevention of acute thrombosis after PTA.
